Leriglitazone Improves Motor Function in Early Symptomatic AMN Patients

Leriglitazone Improves Motor Function in Early Symptomatic AMN Patients

285266

Leriglitazone Improves Motor Function in Early Symptomatic AMN Patients

Treatment with Minoryx Therapeutics’ leriglitazone in a Phase 2/3 clinical trial was found to improve motor function in people with early symptomatic adrenomyeloneuropathy (AMN), one of the most common types of adrenoleukodystrophy (ALD). “On the basis of the overall results from this clinical trial, Minoryx is now preparing for discussions with regulatory authorities for defining a path forward for registration of leriglitazone for AMN sufferers,” Marc Martinell, CEO of Minoryx, said in a press release. Leriglitazone,…

You must be logged in to read/download the full post.